title: Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
abstract: The majority of patients with atrial fibrillation should receive oral anticoagulation to reduce the risk of stroke. The limitations of vitamin K antagonists have led to an underuse of anticoagulants in clinical practice which has been associated with a higher risk of stroke, hospitalizations and healthcare costs. Direct oral anticoagulants (DOACs) overcome some of the limitations of vitamin K antagonists and may therefore increase the use of oral anticoagulants in clinical practice. Since no head-to-head trials have been performed, only indirect comparisons can be made among them. In this review, the results of the Phase III randomized controlled trials with DOACs were analyzed, trying to determine whether one or more DOACs could be especially recommended according to different clinical conditions.
authors.affiliation: Department of Cardiology, University Hospital Ramón y Cajal, University of Alcalá, Madrid, Spain.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.affiliation: Department of Neurology, University Hospital Ramón y Cajal, University of Alcalá, Madrid, Spain.
authors.forename: Jaime
authors.initials: J
authors.lastname: Masjuan
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000150:complications*; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran / Q000008:administration & dosage; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011728:Pyridones / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban / Q000008:administration & dosage; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013844:Thiazoles / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban
keywords: anticoagulation; apixaban; atrial fibrillation; dabigatran; edoxaban; rivaroxaban; treatment